Key result
Ultra-low-dose oral estradiol and dydrogesterone linked to lower baPWV in postmenopausal women over 12 months.
Why the study?
The effect of ultra-low-dose estradiol on vascular function in postmenopausal women has not been clarified.
Does oral ultra-low-dose estradiol and dydrogesterone improve arterial stiffness in postmenopausal women?
Cohort (n=28)
Does oral ultra-low-dose estradiol and dydrogesterone improve arterial stiffness in postmenopausal women?
p-value: p=0.037
Ultra-low-dose estradiol and dydrogesterone therapy for 12 months significantly reduces arterial stiffness in postmenopausal women.
May reduce arterial stiffness with ultra-low-dose HRT in postmenopausal women; hypothesis-generating observational data requiring RCT confirmation.
Background Ultra-low-dose estradiol is known to improve menopausal symptoms and increase bone mineral density. However, the effect of ultra-low-dose estradiol on vascular function has not been clarified. Objectives We examined the effects of ultra-low-dose estradiol on brachial-ankle pulse wave velocity (baPWV) and circulating markers of cardiovascular risk. Patients and methods Twenty-eight postmenopausal women were enrolled in this study. Fourteen women received oral estradiol (0.5 mg) and dydrogesterone (5 mg) every day for 12 months (ultra-low-dose group) as hormone replacement therapy (HRT) and 14 women as a control group did not receive HRT. The baPWV, lipid profiles, homeostasis model assessment of insulin resistance (HOMA-IR) and vascular inflammatory markers were measured. Results The baPWV level significantly decreased in the ultra-low-dose group (p = 0.037), while the baPWV level did not significantly change in the control group. HOMA-IR tended to decrease in the ultra-low-dose group (p = 0.076). Systolic blood pressure and diastolic blood pressure did not change significantly in either group. Conclusion An HRT regimen using oral ultra-low-dose estradiol and dydrogesterone has an effect on arterial stiffness and insulin resistance.
No takes yet. Share an insight, caveat, or question.
Matsui et al. (2013) conducted a cohort in Postmenopausal women (n=28). Ultra-low-dose oral estradiol and dydrogesterone vs. No hormone replacement therapy was evaluated on brachial-ankle pulse wave velocity (baPWV) (p=0.037). Ultra-low-dose oral estradiol and dydrogesterone significantly decreased brachial-ankle pulse wave velocity in postmenopausal women over 12 months (p=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: